MetaCap

Citius Pharmaceuticals (CTXR) vs NewcelX (NCEL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NewcelX (NCEL) has outperformed Citius Pharmaceuticals (CTXR) over the past year, losing 22.3% versus a loss of 55.4%. Over five years, CTXR leads with a -98.8% price change compared with -99.7% for NCEL. NewcelX is the larger company by market cap ($14.7 million vs $14.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTXR-55.39%NCEL-22.32%
+56%-9%-73%
Nov 21, 20251 yearNov 20, 2026
CTXR-98.81%NCEL-99.68%
+16%-45%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTXR versus NCEL key metrics
MetricCTXRNCEL
Share price$0.5085$2.54
Market cap$13.96M$14.67M
1-day change+2.27%-5.58%
YTD return-34.56%+33.68%
1-year return-55.39%-22.32%
5-year return-98.79%-99.65%
P/E ratio (TTM)—4.88
EPS (TTM)$-1.75$0.52
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-39.74M$-8.30M
52-week high$1.54$5.12
52-week low$0.37$1.83
Distance from 52-week high-66.98%-50.39%
Analyst consensusnonenone
Avg. price target upside+686.63%+805.51%
Average volume275.44K13.34K
Shares outstanding27.45M5.78M
Employees239
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NCEL has outperformed CTXR by 33.1 percentage points over the past year.

About Citius Pharmaceuticals

CTXR stock →

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

About NewcelX

NCEL stock →

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

CTXR vs NCEL FAQ

Which is bigger, Citius Pharmaceuticals or NewcelX?

NewcelX (NCEL) is larger, with a market capitalization of $14.67M compared with $13.96M for Citius Pharmaceuticals (CTXR).

Which stock has performed better over the past year, CTXR or NCEL?

NCEL returned -22.32% over the past 12 months, compared with -55.39% for CTXR (price return, excluding dividends). Past performance does not predict future results.

Are Citius Pharmaceuticals and NewcelX in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons